William Blair analyst Matt Phipps has maintained their neutral stance on KROS stock, giving a Hold rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matt Phipps has given his Hold rating due to a combination of factors, primarily focusing on Keros Therapeutics’ current strategic direction and financial position. The company is concentrating its efforts on the development of KER-065, with plans to begin a Phase II trial for Duchenne muscular dystrophy (DMD) in early 2026. This focus on a single product pipeline indicates a high level of commitment but also presents a risk if the trials do not proceed as expected.
Additionally, Keros has initiated a significant capital return of $375 million, which could impact its financial flexibility in the near term. While the potential milestones from the elritercept license agreement with Takeda could provide future financial benefits, these are contingent on successful development and commercialization. Given these factors, Phipps believes that a Hold rating is appropriate as the company navigates these developments and uncertainties.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KROS in relation to earlier this year.